EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration

Andrea Frustaci iD, Nicola Galea iD, Lorenzo Dominici, Romina Verardo, Maria Alfarano, Rossella Scialla iD, Antonio Giovanni Richetta iD

Journal of Clinical Medicine · 12.06.2023 · 12 (12) · 4010

DOI: 10.3390/jcm12124010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.06.2023. Verfasst von Andrea Frustaci und 6 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS San Raffaele, Via di Val Cannuta, 00166 Rome, Italy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IRCCS San Raffaele Roma - Ricerca Corrente, Mebic San Raffaele Pisana, Investigator Initiated Research grant from Takeda Pharmaceuticals International AG, a member of the Takeda group of companies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Psoriasis (PS) is a common immune-mediated disease of the skin with possible extension to joints, aorta and eye. Myocardial inflammation has rarely been suggested. (2)

Aims

Report of PS-related myocarditis. (3) Methods and Results: One hundred consecutive patients with PS were screened for cardiac involvement. Among them, five male patients (aged 56 ± 9.5 years) with a moderate–severe form of PS showed dilated cardiomyopathy (LVEF < 35%) with normal coronary arteries and valves. They underwent a left-ventricular endomyocardial biopsy for evaluation of myocardial substrate. Endomyocardial samples were processed for histology and immunohistochemistry, including myocardial expression of Toll-Like Receptor 4 (TLR4) and interleukin-17A (IL-17A), which play a major role in PS pathogenesis. Real-time PCRs were carried out for cardiotropic viruses, and Western blot analysis was conducted for myocardial expression of IL-17A. Patients’ sera were tested for anti-heart autoantibodies. Active lymphocytic myocarditis was revealed in all five patients, characterized by an absence of viral genomes with PCR, positive anti-heart autoantibodies, overexpression of TLR-4 and enhancement of IL-17-A during western blot analysis, showing a 2.48-fold increase in psoriatic myocarditis compared with no psoriatic myocarditis and a six-fold increase compared to myocardial controls. Treatment included combination of prednisone (1 mg/kg daily for 4 weeks, tapered to 0.33 mg/kg) and azathioprine (2 mg/kg, daily) in 3 pts or secukinumab (SK, 150 mg/weekly for 4 weeks followed by 150 mg/monthly) in 2 pts for 6 months. LVEDD and LVEF improved in the first 3 pts (−14% and + 118%, respectively), while they completely recovered (LVEF > 50%) in the last 2 pts on SK. (4)

Conclusions

IL-17A-related myocarditis can occur in up to 5% of patients with PS. It manifests as progressive dilated cardiomyopathy. It may completely recover following SK administration.

Schlagwörter

Stichwörter der Autor:innen

IL-17Adilated cardiomyopathymyocarditispsoriasis

Autor:innen und Institutionen

  • IRCCS San Raffaele, Via di Val Cannuta, 00166 Rome, Italy.
  • Department of Clinical, Internal, Anesthesiologist and Cardiovascular Sciences, Sapienza University, 00185 Rome, Italy.
  • Cellular and Molecular Cardiology Lab, IRCCS L. Spallanzani, 00149 Rome, Italy.

ORCID-Profile: Andrea Frustaci, Nicola Galea, Rossella Scialla, Antonio Giovanni Richetta

Förderung

  • IRCCS San Raffaele Roma - Ricerca Corrente
  • Mebic San Raffaele Pisana
  • Investigator Initiated Research grant from Takeda Pharmaceuticals International AG, a member of the Takeda group of companies
  • local negotiation agreement – Frustaci
  • Italian Health Ministry I.N.M.I. L. Spallanzani IR.C.C.S , IRCCS San Raffaele Roma
  • Fondazione Roma

Zitieren

APA

Frustaci, A., Galea, N., Dominici, L., Verardo, R., Alfarano, M., Scialla, R., & Richetta, A. G. (2023). Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration. Journal of Clinical Medicine, 12(12), 4010. https://doi.org/10.3390/jcm12124010

Vancouver

Frustaci A, Galea N, Dominici L, Verardo R, Alfarano M, Scialla R, et al. Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration. Journal of Clinical Medicine. 2023;12(12):4010. doi:10.3390/jcm12124010

BibTeX
@article{Frustaci2023,
  author = {Frustaci, Andrea and Galea, Nicola and Dominici, Lorenzo and Verardo, Romina and Alfarano, Maria and Scialla, Rossella and Richetta, Antonio Giovanni},
  title = {Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {12},
  pages = {4010},
  doi = {10.3390/jcm12124010}
}
Kostenlos starten →